Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses

Journal of Hepatology

Volumn 67, Issue 2, 2017, Pages 224-236

  Welzel, Tania M ^a   Bhardwaj, Neeru ^b   Hedskog, Charlotte ^b   Chodavarapu, Krishna ^b   Camus, Gregory ^b   McNally, John ^b   Brainard, Diana ^b   Miller, Michael D ^b   Mo, Hongmei ^b   Svarovskaia, Evguenia ^b   Jacobson, Ira ^c   Zeuzem, Stefan ^a   Agarwal, Kosh ^d  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b GILEAD SCIENCES   (United States)

^c BETH ISRAEL MEDICAL CENTER   (United States)

^d KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Antiviral agents; Deep sequencing; Genotype; Hepatitis C virus; Resistance; Subtypes

Indexed keywords

ANTIVIRUS AGENT; VIRAL PROTEIN;

AMINO ACID SEQUENCE; AMPLICON; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; COMPARATIVE STUDY; GEOGRAPHIC DISTRIBUTION; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 1A; HEPATITIS C VIRUS GENOTYPE 1B; HEPATITIS C VIRUS GENOTYPE 1C; HEPATITIS C VIRUS GENOTYPE 1E; HEPATITIS C VIRUS GENOTYPE 1G; HEPATITIS C VIRUS GENOTYPE 1H; HEPATITIS C VIRUS GENOTYPE 1L; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 2A; HEPATITIS C VIRUS GENOTYPE 2B; HEPATITIS C VIRUS GENOTYPE 2C; HEPATITIS C VIRUS GENOTYPE 2D; HEPATITIS C VIRUS GENOTYPE 2I; HEPATITIS C VIRUS GENOTYPE 2J; HEPATITIS C VIRUS GENOTYPE 2K; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 3A; HEPATITIS C VIRUS GENOTYPE 3B; HEPATITIS C VIRUS GENOTYPE 3G; HEPATITIS C VIRUS GENOTYPE 3H; HEPATITIS C VIRUS GENOTYPE 3I; HEPATITIS C VIRUS GENOTYPE 3K; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 4A; HEPATITIS C VIRUS GENOTYPE 4B; HEPATITIS C VIRUS GENOTYPE 4C; HEPATITIS C VIRUS GENOTYPE 4D; HEPATITIS C VIRUS GENOTYPE 4F; HEPATITIS C VIRUS GENOTYPE 4K; HEPATITIS C VIRUS GENOTYPE 4L; HEPATITIS C VIRUS GENOTYPE 4M; HEPATITIS C VIRUS GENOTYPE 4N; HEPATITIS C VIRUS GENOTYPE 4O; HEPATITIS C VIRUS GENOTYPE 4R; HEPATITIS C VIRUS GENOTYPE 4T; HEPATITIS C VIRUS GENOTYPE 5; HEPATITIS C VIRUS GENOTYPE 5A; HEPATITIS C VIRUS GENOTYPE 6; HEPATITIS C VIRUS GENOTYPE 6 NOVEL/MIXED; HEPATITIS C VIRUS GENOTYPE 6A; HEPATITIS C VIRUS GENOTYPE 6E; HEPATITIS C VIRUS GENOTYPE 6F; HEPATITIS C VIRUS GENOTYPE 6G; HEPATITIS C VIRUS GENOTYPE 6H; HEPATITIS C VIRUS GENOTYPE 6I; HEPATITIS C VIRUS GENOTYPE 6L; HEPATITIS C VIRUS GENOTYPE 6M; HEPATITIS C VIRUS GENOTYPE 6N; HEPATITIS C VIRUS GENOTYPE 6O; HEPATITIS C VIRUS GENOTYPE 6P; HEPATITIS C VIRUS GENOTYPE 6Q; HEPATITIS C VIRUS GENOTYPE 6R; HEPATITIS C VIRUS GENOTYPE 7; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; MAJOR CLINICAL STUDY; MOLECULAR EPIDEMIOLOGY; MOLECULAR PHYLOGENY; NONHUMAN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHYLOGENETIC TREE; PREVALENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS RECOMBINANT; WHOLE GENOME SEQUENCING; CLASSIFICATION; DRUG EFFECTS; GENETICS; GENOTYPE; HEPACIVIRUS; HIGH THROUGHPUT SEQUENCING; PHYLOGENY; VIROLOGY;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MOLECULAR EPIDEMIOLOGY; PHYLOGENY; PREVALENCE; SEQUENCE ANALYSIS, RNA; VIRAL NONSTRUCTURAL PROTEINS;

EID: 85019836059     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2017.03.014     Document Type: Article

References (41)

1. Shepard, C.W., Finelli, L., Alter, M.J., Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5 (2005), 558–567.
2. Lauer, G.M., Walker, B.D., Hepatitis C virus infection. N Engl J Med 345 (2001), 41–52.
3. Smith, D.B., Bukh, J., Kuiken, C., Muerhoff, A.S., Rice, C.M., Stapleton, J.T., et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 59 (2014), 318–327.
4. Timm, J., Roggendorf, M., Sequence diversity of hepatitis C virus: implications for immune control and therapy. World J Gastroenterol 13 (2007), 4808–4817.
5. Asselah, T., Boyer, N., Saadoun, D., Martinot-Peignoux, M., Marcellin, P., Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. Liver Int 36 (2016), 47–57.
6. Sulkowski, M.S., Gardiner, D.F., Rodriguez-Torres, M., Reddy, K.R., Hassanein, T., Jacobson, I., et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 370 (2014), 211–221.
7. Lawitz, E., Mangia, A., Wyles, D., Rodriguez-Torres, M., Hassanein, T., Gordon, S.C., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 368 (2013), 1878–1887.
8. Feld, J.J., Jacobson, I.M., Hezode, C., Asselah, T., Ruane, P.J., Gruener, N., et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 373 (2015), 2599–2607.
9. Foster, G.R., Afdhal, N., Roberts, S.K., Brau, N., Gane, E.J., Pianko, S., et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 373 (2015), 2608–2617.
10. Gower, E., Estes, C., Blach, S., Razavi-Shearer, K., Razavi, H., Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 61 (2014), S45–S57.
11. Messina, J.P., Humphreys, I., Flaxman, A., Brown, A., Cooke, G.S., Pybus, O.G., et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61 (2015), 77–87.
12. Rehman, I.U., Idrees, M., Ali, M., Ali, L., Butt, S., Hussain, A., et al. Hepatitis C virus genotype 3a with phylogenetically distinct origin is circulating in Pakistan. Genet Vaccines Ther, 9, 2011, 2.
13. McNaughton, A.L., Cameron, I.D., Wignall-Fleming, E.B., Biek, R., McLauchlan, J., Gunson, R.N., et al. Spatiotemporal reconstruction of the introduction of hepatitis C virus into Scotland and its subsequent regional transmission. J Virol 89 (2015), 11223–11232.
14. Akkarathamrongsin, S., Hacharoen, P., Tangkijvanich, P., Theamboonlers, A., Tanaka, Y., Mizokami, M., et al. Molecular epidemiology and genetic history of hepatitis C virus subtype 3a infection in Thailand. Intervirology 56 (2013), 284–294.
15. Karchava, M., Waldenstrom, J., Parker, M., Hallack, R., Sharvadze, L., Gatserelia, L., et al. High incidence of the hepatitis C virus recombinant 2k/1b in Georgia: Recommendations for testing and treatment. Hepatol Res 45 (2015), 1292–1298.
16. Raghwani, J., Thomas, X.V., Koekkoek, S.M., Schinkel, J., Molenkamp, R., van de Laar, T.J., et al. Origin and evolution of the unique hepatitis C virus circulating recombinant form 2k/1b. J Virol 86 (2012), 2212–2220.
17. Kalinina, O., Norder, H., Mukomolov, S., Magnius, L.O., A natural intergenotypic recombinant of hepatitis C virus identified in St Petersburg. J Virol 76 (2002), 4034–4043.
18. Wyles, D.L., Antiviral resistance and the future landscape of hepatitis C virus infection therapy. J Infect Dis 207 (2013), S33–S39.
19. Paolucci, S., Fiorina, L., Mariani, B., Gulminetti, R., Novati, S., Barbarini, G., et al. Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naive patients. Virol J, 10, 2013, 355.
20. Sarrazin, C., Lathouwers, E., Peeters, M., Daems, B., Buelens, A., Witek, J., et al. Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region. Antiviral Res 116 (2015), 10–16.
21. Stuyver, L., Rossau, R., Wyseur, A., Duhamel, M., Vanderborght, B., Van Heuverswyn, H., et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 74 (1993), 1093–1102.
22. Stuyver, L., Wyseur, A., van Arnhem, W., Lunel, F., Laurent-Puig, P., Pawlotsky, J.M., et al. Hepatitis C virus genotyping by means of 5’-UR/core line probe assays and molecular analysis of untypeable samples. Virus Res 38 (1995), 137–157.
23. Altschul, S.F., Madden, T.L., Schaffer, A.A., Zhang, J., Zhang, Z., Miller, W., et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 25 (1997), 3389–3402.
24. Hedskog, C., Chodavarapu, K., Ku, K.S., Xu, S., Martin, R., Miller, M.D., et al. Genotype- and subtype-independent full-genome sequencing assay for hepatitis C virus. J Clin Microbiol 53 (2015), 2049–2059.
25. Thompson, J.D., Higgins, D.G., Gibson, T.J., CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22 (1994), 4673–4680.
26. Zwickl, D.J., Genetic algorithm approaches for the phylogenetic analysis of large biological sequence datasets under the maximum likelihood criterion. Ph.D. dissertation, 2006, The University of Texas at Austin.
27. Anisimova, M., Gascuel, O., Approximate likelihood-ratio test for branches: A fast, accurate, and powerful alternative. Syst Biol 55 (2006), 539–552.
28. Guindon, S., Dufayard, J.F., Lefort, V., Anisimova, M., Hordijk, W., Gascuel, O., New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. Syst Biol 59 (2010), 307–321.
29. Hedskog, C., Doehle, B., Chodavarapu, K., Gontcharova, V., Crespo Garcia, J., De Knegt, R., et al. Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirin. Hepatology 61 (2015), 471–480.
30. Schreiber, J., McNally, J., Chodavarapu, K., Svarovskaia, E., Moreno, C., Treatment of a patient with genotype 7 HCV infection with sofosbuvir and velpatasvir. Hepatology 64:3 (2016), 983–985.
31. Frank, C., Mohamed, M.K., Strickland, G.T., Lavanchy, D., Arthur, R.R., Magder, L.S., et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 355 (2000), 887–891.
32. Lin, M.V., Chung, R., Recent FDA approval of sofosbuvir and simeprevir. Implications for current HCV treatment. Clin Liver Dis 3 (2014), 65–68.
33. Kumada, H., Suzuki, Y., Ikeda, K., Toyota, J., Karino, Y., Chayama, K., et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 59 (2014), 2083–2091.
34. Nakamoto, S., Kanda, T., Wu, S., Shirasawa, H., Yokosuka, O., Hepatitis C virus NS5A inhibitors and drug resistance mutations. World J Gastroenterol 20 (2014), 2902–2912.
35. Lam, A.M., Espiritu, C., Bansal, S., Micolochick Steuer, H.M., Niu, C., Zennou, V., et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother 56 (2012), 3359–3368.
36. Bouchardeau, F., Cantaloube, J.F., Chevaliez, S., Portal, C., Razer, A., Lefrere, J.J., et al. Improvement of hepatitis C virus (HCV) genotype determination with the new version of the INNO-LiPA HCV assay. J Clin Microbiol 45 (2007), 1140–1145.
37. De Keukeleire, S., Descheemaeker, P., Reynders, M., Diagnosis of hepatitis C virus genotype 2k/1b needs NS5B sequencing. Int J Infect Dis 41 (2015), 1–2.
38. Noppornpanth, S., Sablon, E., De Nys, K., Truong, X.L., Brouwer, J., Van Brussel, M., et al. Genotyping hepatitis C viruses from Southeast Asia by a novel line probe assay that simultaneously detects core and 5’ untranslated regions. J Clin Microbiol 44 (2006), 3969–3974.
39. Svarovskaia, E.S., Gane, E., Dvory-Sobol, H., Martin, R., Doehle, B., Hedskog, C., et al. L159F and V321A sofosbuvir-associated hepatitis C virus NS5B substitutions. J Infect Dis 213 (2016), 1240–1247.
40. Abergel, A., Metivier, S., Samuel, D., Jiang, D., Kersey, K., Pang, P.S., et al. Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection. Hepatology 64:4 (2016), 1049–1056.
41. Zeuzem, S., Mizokami, M., Pianko, S., Mangia, A., Han, K.H., Martin, R., et al. NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome. J Hepatol 66 (2017), 910–918.